Literature DB >> 25795441

Repeated ketamine administration redeems the time lag for citalopram's antidepressant-like effects.

G-F Zhang1, W-X Liu1, L-L Qiu1, J Guo2, X-M Wang1, H-L Sun1, J-J Yang3, Z-Q Zhou4.   

Abstract

Current available antidepressants exhibit low remission rate with a long response lag time. Growing evidence has demonstrated acute sub-anesthetic dose of ketamine exerts rapid, robust, and lasting antidepressant effects. However, a long term use of ketamine tends to elicit its adverse reactions. The present study aimed to investigate the antidepressant-like effects of intermittent and consecutive administrations of ketamine on chronic unpredictable mild stress (CUMS) rats, and to determine whether ketamine can redeem the time lag for treatment response of classic antidepressants. The behavioral responses were assessed by the sucrose preference test, forced swimming test, and open field test. In the first stage of experiments, all the four treatment regimens of ketamine (10mg/kg ip, once daily for 3 or 7 consecutive days, or once every 7 or 3 days, in a total 21 days) showed robust antidepressant-like effects, with no significant influence on locomotor activity and stereotype behavior in the CUMS rats. The intermittent administration regimens produced longer antidepressant-like effects than the consecutive administration regimens and the administration every 7 days presented similar antidepressant-like effects with less administration times compared with the administration every 3 days. In the second stage of experiments, the combination of ketamine (10 mg/kg ip, once every 7 days) and citalopram (20 mg/kg po, once daily) for 21 days caused more rapid and sustained antidepressant-like effects than citalopram administered alone. In summary, repeated sub-anesthestic doses of ketamine can redeem the time lag for the antidepressant-like effects of citalopram, suggesting the combination of ketamine and classic antidepressants is a promising regimen for depression with quick onset time and stable and lasting effects.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Behavior; Citalopram; Depression; Ketamine

Mesh:

Substances:

Year:  2015        PMID: 25795441     DOI: 10.1016/j.eurpsy.2014.11.007

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  9 in total

1.  Ketamine for depression: evidence, challenges and promise.

Authors:  Carlos A Zarate; Mark J Niciu
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

2.  Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the anti-apoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression.

Authors:  Wen-Xue Liu; Jing Wang; Ze-Min Xie; Ning Xu; Guang-Fen Zhang; Min Jia; Zhi-Qiang Zhou; Kenji Hashimoto; Jian-Jun Yang
Journal:  Psychopharmacology (Berl)       Date:  2015-10-29       Impact factor: 4.530

3.  Ketamine Tolerance in Sprague-Dawley Rats after Chronic Administration of Ketamine, Morphine, or Cocaine.

Authors:  Samantha A Gerb; Jemma E Cook; Alexandria E Gochenauer; Camille S Young; Lindak K Fulton; Andrew W Grady; Kevin B Freeman
Journal:  Comp Med       Date:  2019-01-29       Impact factor: 0.982

4.  The Potential Antidepressant Action of Duloxetine Co-Administered with the TAAR1 Receptor Agonist SEP-363856 in Mice.

Authors:  Xia Ren; Jiaying Xiong; Lingzhi Liang; Yin Chen; Guisen Zhang
Journal:  Molecules       Date:  2022-04-25       Impact factor: 4.927

5.  Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.

Authors:  Marie Spies; Gregory M James; Neydher Berroterán-Infante; Harald Ibeschitz; Georg S Kranz; Jakob Unterholzner; Mathis Godbersen; Gregor Gryglewski; Marius Hienert; Johannes Jungwirth; Verena Pichler; Birgit Reiter; Leo Silberbauer; Dietmar Winkler; Markus Mitterhauser; Thomas Stimpfl; Marcus Hacker; Siegfried Kasper; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2018-02-01       Impact factor: 5.176

6.  Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.

Authors:  Ze-Min Xie; Xing-Ming Wang; Ning Xu; Jing Wang; Wei Pan; Xiao-Hui Tang; Zhi-Qiang Zhou; Kenji Hashimoto; Jian-Jun Yang
Journal:  Sci Rep       Date:  2017-06-09       Impact factor: 4.379

7.  NLRP1-Mediated Antidepressant Effect of Ketamine in Chronic Unpredictable Mild Stress Model in Rats.

Authors:  Feyza Aricioğlu; Canan Yalcinkaya; Ceren Sahin Ozkartal; Erdem Tuzun; Serap Sirvanci; Cem Ismail Kucukali; Tijen Utkan
Journal:  Psychiatry Investig       Date:  2020-03-24       Impact factor: 2.505

8.  The influence of ketamine's repeated treatment on brain topology does not suggest an antidepressant efficacy.

Authors:  Natalia Gass; Robert Becker; Jonathan Reinwald; Alejandro Cosa-Linan; Markus Sack; Wolfgang Weber-Fahr; Barbara Vollmayr; Alexander Sartorius
Journal:  Transl Psychiatry       Date:  2020-02-04       Impact factor: 6.222

9.  Repeated but Not Single Administration of Ketamine Prolongs Increases of the Firing Activity of Norepinephrine and Dopamine Neurons.

Authors:  Chidiebere M Iro; Rami Hamati; Mostafa El Mansari; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2021-07-23       Impact factor: 5.176

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.